CAS · 608141-41-9
Product Overview
ApreMilast is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | White to light yellow solid crystal |
|---|---|
| Purity | 99.0% min |
| Assay | 98% - 102% |
| Identification | IR absorption spectrum and retention time consistent with reference |
| 1,3-Dioxo-2-isoindolineacetic acid | 0.1% max |
| (S)-13-O-hydroxy-4-Methyl-methyloyl)ethylamide N-acetyl-L-leucine salt | 0.1% max |
| Unknown single impurity | 0.1% max |
| Total impurities | 1.0% max |
| Melting point | 154 - 158 °C |
| Heavy metals | 10 ppm max |
| Residue on ignition | 0.1% max |
| Acetone | 5000 ppm max |
| Ethanol | 5000 ppm max |
| Dichloromethane | 600 ppm max |
| Water | 0.5% max |
| Loss on drying | 0.5% max |
| Chiral isomers | 1.0% max |
Applications
1. Psoriasis and Psoriatic Arthritis
● Approved treatment for moderate to severe plaque psoriasis.
● Reduces skin inflammation, scaling, and joint pain.
● Alternative to biologic agents; convenient oral administration.
2. Behçet's Disease
● FDA-approved for treatment of oral ulcers associated with Behçet's disease.
● Offers effective symptom control with a good safety profile.
3. Atopic Dermatitis and Other Autoimmune Disorders (investigational)
● Under investigation or off-label use for:
Atopic dermatitis
Rheumatoid arthritis
Lupus erythematosus
Inflammatory bowel disease (IBD)
4. Potential Antiviral/Antifibrotic Uses (emerging research)
● PDE4 inhibitors like apremilast are being studied for their immune-modulating roles in viral infections and fibrotic diseases (e.g., pulmonary fibrosis).
Benefits
✅ Oral Dosage Form
● No injections or infusions needed, enhancing patient convenience and compliance.
✅ Targeted Immunomodulation
● Balances cytokine signaling without broad immune suppression, reducing the risk of infections and cancer.
✅ Well-Tolerated
● Most side effects are mild to moderate (e.g., nausea, diarrhea, headache) and often resolve over time.
✅ Steroid- and Biologic-Sparing Agent
● Allows reduction or avoidance of corticosteroids and injectable biologics.
Conclusion
ApreMilast丨CAS 608141-41-9 is a cutting-edge PDE4 inhibitor offering a non-biologic oral treatment option for chronic inflammatory diseases like psoriasis, psoriatic arthritis, and Behçet's disease. Its balanced efficacy, safety profile, and oral administration position it as a valuable therapeutic agent in autoimmune and inflammatory conditions.
Hot Tags: apremilast丨cas 608141-41-9, China apremilast丨cas 608141-41-9 manufacturers, suppliers, factory, 59-30-3, CAS 107133 36 8, Ciclopirox ethanolamine, CAS 39537 23 0, CAS 98319 26 7, CAS 1263 89 4
Previous
Ertapenem Sodium丨CAS 153773-82-1
Next